Payment overview · 2025
General Payments
$1,719.71
107 reported records · 24 companies
Healthcare provider profile · identity verified
Michael Christopher Desantis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HICKORY, NC · NPI 1780610394
Verified facts
What the public records show
CMS Open Payments records show Michael Christopher Desantis, M.D. received $1,719.71 in general payments during 2025 across 107 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 959 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $449.21 | 26.1% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $231.84 | 13.5% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $139.69 | 8.1% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.17 | 6.2% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.00 | 5.9% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.31 | 5.6% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.19 | 5.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.43 | 3.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $65.01 | 3.8% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $58.67 | 3.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.21 | 2.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $37.78 | 2.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.88 | 2.0% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.06 | 1.7% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.93 | 1.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.19 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.58 | 1.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.65 | 1.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.63 | 1.0% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $16.57 | 1.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.64 | 0.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.54 | 0.9% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.54 | 0.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.99 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,719.71 | 107 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $232.94 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $145.99 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $124.31 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $122.89 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $121.96 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.55 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $89.31 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $85.85 | 13 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.19 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $78.93 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.43 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $65.01 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.20 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.72 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $57.25 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.04 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.04 | 3 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $48.92 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $48.92 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.21 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.80 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.13 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $29.06 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.38 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 34 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 959 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 75 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 71 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 159 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
159 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
75 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
71 | 18 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
959 | 98 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1316 | 262 |
| Lisinopril | Lisinopril | 1124 | 224 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1112 | 167 |
| Eliquis | Apixaban | 959 | 98 |
| Omeprazole | Omeprazole | 953 | 180 |
| Amlodipine Besylate | Amlodipine Besylate | 946 | 184 |
| Trazodone Hcl | Trazodone Hcl | 613 | 110 |
| Furosemide | Furosemide | 610 | 123 |
| Gabapentin | Gabapentin | 610 | 94 |
| Donepezil Hcl | Donepezil Hcl | 564 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 559 | 109 |
| Losartan Potassium | Losartan Potassium | 527 | 109 |
| Sertraline Hcl | Sertraline Hcl | 524 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 471 | 110 |
| Escitalopram Oxalate | Escitalopram Oxalate | 463 | 70 |
| Metformin Hcl | Metformin Hcl | 430 | 87 |
| Potassium Chloride | Potassium Chloride | 392 | 73 |
| Simvastatin | Simvastatin | 373 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 367 | 74 |
| Memantine Hcl | Memantine Hcl | 340 | 40 |
| Myrbetriq | Mirabegron | 320 | 24 |
| Buspirone Hcl | Buspirone Hcl | 312 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 310 | 58 |
| Citalopram Hbr | Citalopram Hydrobromide | 264 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 262 | 46 |
| Divalproex Sodium | Divalproex Sodium | 248 | 34 |
| Montelukast Sodium | Montelukast Sodium | 235 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 33 |
| Mirtazapine | Mirtazapine | 222 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 208 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 205 | 47 |
| Carvedilol | Carvedilol | 201 | 40 |
| Famotidine | Famotidine | 199 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 197 | 25 |
| Meloxicam | Meloxicam | 191 | 44 |
| Allopurinol | Allopurinol | 177 | 40 |
| Alendronate Sodium | Alendronate Sodium | 176 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 162 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 159 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 158 | 42 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 156 | 38 |
| Prednisone | Prednisone | 155 | 81 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 31 |
| Warfarin Sodium | Warfarin Sodium | 149 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 30 |
| Tramadol Hcl | Tramadol Hcl | 138 | 41 |
| Glimepiride | Glimepiride | 137 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 22 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 127 | 58 |
| Ezetimibe | Ezetimibe | 121 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 116 | 20 |
| Tradjenta | Linagliptin | 114 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 114 | 19 |
| Bupropion Xl | Bupropion Hcl | 110 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 106 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 101 | 53 |
| Nystatin | Nystatin | 93 | 48 |
| Spironolactone | Spironolactone | 92 | 21 |
| Baclofen | Baclofen | 91 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 36 |
| Alprazolam | Alprazolam | 89 | 18 |
| Metformin Hcl Er | Metformin Hcl | 87 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 18 |
| Xarelto | Rivaroxaban | 77 | suppressed |
| Levofloxacin | Levofloxacin | 76 | 66 |
| Jardiance | Empagliflozin | 75 | suppressed |
| Celecoxib | Celecoxib | 72 | 20 |
| Atenolol | Atenolol | 71 | 14 |
| Cephalexin | Cephalexin | 71 | 47 |
| Ozempic | Semaglutide | 71 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 70 | 18 |
| Januvia | Sitagliptin Phosphate | 70 | suppressed |
| Valsartan | Valsartan | 70 | 15 |
| Latanoprost | Latanoprost | 68 | suppressed |
| Lovastatin | Lovastatin | 66 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | suppressed |
| Finasteride | Finasteride | 62 | 17 |
| Olanzapine | Olanzapine | 61 | suppressed |
| Lorazepam | Lorazepam | 60 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 48 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 14 |
| Novolog Flexpen | Insulin Aspart | 58 | 13 |
| Risperidone | Risperidone | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 56 | 13 |
| Azithromycin | Azithromycin | 55 | 52 |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 51 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 50 | 13 |
| Torsemide | Torsemide | 48 | suppressed |
| Trimethoprim | Trimethoprim | 47 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 44 | suppressed |
| Mupirocin | Mupirocin | 43 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 37 |
| Dexlansoprazole Dr | Dexlansoprazole | 42 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 13 |
| Cefdinir | Cefdinir | 41 | 38 |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 41 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 34 |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Gemtesa | Vibegron | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Humulin R | Insulin Regular, Human | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 36 | 13 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 36 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 34 | 31 |
| Trulicity | Dulaglutide | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 24 |
| Gentamicin Sulfate | Gentamicin Sulfate | 32 | 23 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 32 | suppressed |
| Novolin R | Insulin Regular, Human | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 24 |
| Nystop | Nystatin | 30 | 17 |
| Rivastigmine | Rivastigmine Tartrate | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Rivastigmine | Rivastigmine | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 26 | suppressed |
| Budesonide | Budesonide | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Silodosin | Silodosin | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Letrozole | Letrozole | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | 13 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 12 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Erythromycin | Erythromycin Base | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Alphagan P | Brimonidine Tartrate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 18 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 13 |
| Potassium Citrate Er | Potassium Citrate | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 14 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | 13 |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxazepam | Oxazepam | 13 | suppressed |
| Propylthiouracil | Propylthiouracil | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,719.71 · 107 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, AREXVY, AUSTEDO XR, BEYFORTUS, BREZTRI, CAPLYTA, COMIRNATY, CREXONT, Cologuard Collection Kit, Dyanavel XR, ELIQUIS, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, HORIZANT, JARDIANCE, JATENZO, Kerendia, MINIMED 780G, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error